TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies.
Saved in:
| Title: | TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies. |
|---|---|
| Authors: | Burris, Howard Howard.Burris@scresearch.net, Kurkjian, C., Hart, L., Pant, S., Murphy, P., Jones, S.1, Neuwirth, R.2, Patel, C.2, Zohren, F.2, Infante, J., Burris, Howard A 3rd3,4 (AUTHOR), Kurkjian, C D3,5 (AUTHOR), Murphy, P B3,4 (AUTHOR), Jones, S F3 (AUTHOR), Patel, C G6 (AUTHOR), Infante, J R3,4 (AUTHOR) |
| Source: | Cancer Chemotherapy & Pharmacology. Aug2017, Vol. 80 Issue 2, p261-273. 13p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
